|  | 24 h | 96 h | 1 week | 3 weeks | ||||
---|---|---|---|---|---|---|---|---|---|
Pathway ID | Pathway name | # Peptides | p-value (FDR) | # Peptides | p-value (FDR) | # Peptides | p-value (FDR) | # Peptides | p-value (FDR) |
hsa05221 | Acute myeloid leukemia | 4 | 0.0227 | 3 | 0.0344 | 2 | 0.228 | 3 | 0.0785 |
hsa04520 | Adherens junction | 4 | 0.0506 | 2 | 0.340 | 2 | 0.332 | 4 | 0.0302 |
hsa04920 | Adipocytokine signaling pathway | 6 | 0.0023 | Â | N/S | 4 | 0.0131 | 7 | 0.0003 |
hsa04360 | Axon guidance | 6 | 0.0191 | 4 | 0.0432 | Â | N/S | Â | N/S |
hsa04662 | B cell receptor signaling pathway | 5 | 0.0123 | 3 | 0.0559 | Â | N/S | 4 | 0.0297 |
hsa04020 | Calcium signaling pathway | 5 | 0.166 | Â | N/S | 6 | 0.0095 | Â | N/S |
hsa04062 | Chemokine signaling pathway | 4 | 0.469 | 5 | 0.0344 | 4 | 0.126 | Â | N/S |
hsa05220 | Chronic myeloid leukemia | 4 | 0.0452 | 4 | 0.0103 | 2 | 0. 318 | 6 | 0.0012 |
hsa05210 | Colorectal cancer | Â | N/S | 4 | 0.0066 | Â | N/S | 3 | 0.0969 |
hsa05213 | Endometrial cancer | 3 | 0.0976 | 4 | 0.0047 | Â | N/S | Â | N/S |
hsa04012 | ErbB signaling pathway | 8 | 0.0001 | 7 | 0.0000 | 4 | 0.0167 | 5 | 0.0097 |
hsa04664 | Fc epsilon RI signaling pathway | 7 | 0.0006 | 5 | 0.0029 | Â | N/S | 6 | 0.0018 |
hsa04666 | Fc gamma R-mediated phagocytosis | 4 | 0.0979 | 4 | 0.0224 | Â | N/S | 5 | 0.0148 |
hsa04510 | Focal adhesion | 8 | 0.0123 | 6 | 0.0115 | Â | N/S | 7 | 0.0154 |
hsa05214 | Glioma | 7 | 0.0001 | 3 | 0.0432 | 6 | 0.0001 | 5 | 0.0033 |
hsa00010 | Glycolysis/Gluconeogenesis | 5 | 0.0064 | 3 | 0.0432 | 3 | 0.0586 | 6 | 0.0008 |
hsa04912 | GnRH signaling pathway | 7 | 0.0015 | 5 | 0.0047 | 4 | 0.0245 | 5 | 0.0151 |
hsa05410 | Hypertrophic cardiomyopathy (HCM) | 3 | 0.264 | Â | N/S | 3 | 0.106 | 6 | 0.0018 |
hsa04910 | Insulin signaling pathway | 13 | 0.0000 | 10 | 0.0000 | 7 | 0.0003 | 16 | 0.0000 |
hsa04730 | Long-term depression | 4 | 0.0449 | 3 | 0.0537 | 4 | 0.0113 | Â | N/S |
hsa04010 | MAPK signaling pathway | 14 | 0.0001 | 13 | 0.0000 | 4 | 0.318 | 11 | 0.0011 |
hsa05218 | Melanoma | 4 | 0.0443 | 4 | 0.0095 | 4 | 0.0113 | 5 | 0.0043 |
hsa04150 | mTOR signaling pathway | 6 | 0.0004 | 3 | 0.0309 | Â | N/S | 5 | 0.0018 |
hsa04722 | Neurotrophin signaling pathway | 6 | 0.0176 | 6 | 0.0020 | 5 | 0.0113 | 7 | 0.0018 |
hsa05223 | Non-small cell lung cancer | 5 | 0.0048 | 3 | 0.0362 | Â | N/S | 4 | 0.0151 |
hsa05212 | Pancreatic cancer | 4 | 0.0418 | 3 | 0.0476 | Â | N/S | 4 | 0.0227 |
hsa05200 | Pathways in cancer | Â | N/S | Â | N/S | 6 | 0.0639 | 9 | 0.0151 |
hsa04914 | Progesterone-mediated oocyte maturation | 5 | 0.0176 | Â | N/S | Â | N/S | 5 | 0.0097 |
hsa05215 | Prostate cancer | 5 | 0.0192 | 4 | 0.0173 | 4 | 0.0169 | 5 | 0.0107 |
hsa04810 | Regulation of actin cytoskeleton | 6 | 0.104 | 6 | 0.0115 | Â | N/S | 6 | 0.0591 |
hsa05211 | Renal cell carcinoma | 4 | 0.0446 | 5 | 0.0018 | Â | N/S | 4 | 0.0254 |
hsa05222 | Small cell lung cancer | Â | N/S | Â | N/S | 2 | 0.397 | 6 | 0.0020 |
hsa04660 | T cell receptor signaling pathway | 6 | 0.0123 | 4 | 0.0344 | Â | N/S | 3 | 0.332 |
hsa04620 | Toll-like receptor signaling pathway | 5 | 0.0403 | 5 | 0.0058 | Â | N/S | 6 | 0.0043 |
hsa04270 | Vascular smooth muscle contraction | 5 | 0.0452 | 3 | 0.139 | Â | N/S | 4 | 0.105 |
hsa04370 | VEGF signaling pathway | 6 | 0.0023 | Â | N/S | Â | N/S | 4 | 0.0302 |